Cochrane · systematic review · CD013337
Pharmacological interventions for prevention of weight gain in people with schizophrenia
Agarwal, SM, Stogios, N, Ahsan, ZA, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
15
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 13 · 46.4%Very low 4 · 14.3%Low 11 · 39.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Metformin compared to placebo or no treatment for prevention of weight gain in people with schizophrenia
Population: people with schizophrenia with antipsychotic‐induced weight gain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Weight: clinically important change in weight (kg) Metformin vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weight: average endpoint/change in weight (kg) Metformin vs placebo or no treatment | no estimate extracted | 4 studies · 131 participants | Low Downgraded: risk of bias, imprecision |
Weight: clinically important change in BMI (kg/m2) Metformin vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weight Average endpoint/change in BMI (kg/m2) Metformin vs placebo or no treatment | no estimate extracted | 5 studies · 227 participants | Low Downgraded: risk of bias, inconsistency |
Leaving the study early: for any reason Metformin vs placebo or no treatment | RR 1.02 [0.25, 4.13] | 4 studies · 137 participants | Very low Downgraded: imprecision, inconsistency |
Compliance with treatment Metformin vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Reports of nausea Metformin vs placebo or no treatment | RR 2.38 [0.28, 19.95] | 2 studies · 69 participants | Low Downgraded: imprecision |
H2 antagonists compared to placebo for prevention of weight gain in people with schizophrenia
Population: people with schizophrenia with antipsychotic‐induced weight gain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Weight: clinically important change in weight (kg) H2 antagonists vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weight: average endpoint/change in body weight (kg) H2 antagonists vs placebo | no estimate extracted | 3 studies · 248 participants | Low Downgraded: risk of bias |
Weight: clinically important change in BMI (kg/m2) H2 antagonists vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weight: average endpoint/change in BMI (kg/m2) H2 antagonists vs placebo | no estimate extracted | 2 studies · 79 participants | Very low Downgraded: risk of bias |
Leaving the study early: for any reason H2 antagonists vs placebo | RR 1.07 [0.72, 1.57] | 2 studies · 189 participants | Low Downgraded: risk of bias |
Compliance with treatment H2 antagonists vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Reports of nausea H2 antagonists vs placebo | RR 1.13 [0.34, 3.68] | 1 study · 175 participants | Low Downgraded: risk of bias |
Monoamine modulators compared to placebo for prevention of weight gain in people with schizophrenia
Population: people with schizophrenia with antipsychotic‐induced weight gain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Weight: clinically important change in weight (kg) Monoamine modulators vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weight: average endpoint/change in body weight (kg) Monoamine modulators vs placebo | no estimate extracted | 3 studies · 103 participants | Low |
Weight: clinically important change in BMI (kg/m2) Monoamine modulators vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weight: average endpoint/change in BMI (kg/m2) Monoamine modulators vs placebo | no estimate extracted | 3 studies · 103 participants | Low |
Leaving the study early: for any reason Monoamine modulators vs placebo | RR 1.05 [0.56, 1.94] | 3 studies · 115 participants | Low |
Compliance with treatment Monoamine modulators vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Reports of nausea Monoamine modulators vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Topiramate compared to placebo or no treatment for prevention of weight gain in people with schizophrenia
Population: people with schizophrenia with antipsychotic‐induced weight gain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Weight: clinically important change in weight (kg) Topiramate vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weight: average endpoint/change in weight (kg) Topiramate vs placebo or no treatment | no estimate extracted | 3 studies · 168 participants | Very low Downgraded: risk of bias |
Weight: clinically important change in BMI (kg/m2) Topiramate vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Weight: average endpoint/change in BMI (kg/m2) Topiramate vs placebo or no treatment | no estimate extracted | 2 studies · 120 participants | Very low Downgraded: risk of bias |
Leaving the study early: for any reason Topiramate vs placebo or no treatment | RR 1.09 [0.85, 1.41] | 2 studies · 132 participants | Low Downgraded: risk of bias |
Compliance with treatment Topiramate vs placebo or no treatment | no estimate extracted | 0 studies · 0 participants | Ungraded |
Reports of nausea Topiramate vs placebo or no treatment | RR 1.2 [0.26, 5.44] | 2 studies · 120 participants | Low Downgraded: risk of bias |